Business Context and Reporting Period
Company: Capricor Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: October 19, 2017
Event: Entry into a Material Definitive Agreement for an "at the market" equity offering.
Key Financial Metrics
This filing does not report historical revenue, profit, cash flow, margins, or debt levels. It details a new financing arrangement with the following parameters:
- Aggregate Offering Price: Up to $14,000,000.
- Sales Agent: H.C. Wainwright & Co., LLC.
- Commission Rate: 3.0% of gross proceeds per share sold.
- Underlying Registration: Form S-3 filed on September 28, 2015.
Material Changes
The primary material change is the execution of a Common Stock Sales Agreement on October 19, 2017. This agreement authorizes the Company to sell shares of its common stock from time to time through the sales agent. The Company retains the right to suspend sales or terminate the agreement at any time.
Guidance, Outlook, and Management Commentary
Use of Proceeds: The Company intends to use net proceeds for:
- Research related to product candidates.
- Manufacturing of products.
- Working capital and general corporate purposes.
- Potential acquisitions or other business combinations.
Management Discretion: The Board of Directors reserves the right to reallocate proceeds based on business developments. The Company states it cannot specify with certainty all particular uses for the net proceeds at this time.
Investor Verification Checklist
- Verify the current number of shares outstanding to assess potential dilution from the $14,000,000 offering.
- Review the full text of the Common Stock Sales Agreement (Exhibit 10.1) for specific termination clauses and sales restrictions.
- Confirm the status of the underlying Form S-3 Registration Statement to ensure it remains effective for the offering.
- Monitor future filings for actual sales volumes and proceeds generated under this agreement.